What's new? Log in Free sign up

Q32 Bio (QTTB)

Company Profile

Company profile

Ticker

QTTB

Exchange

Website

www.homologymedicines.com/

CEO

Ms. Jodie Pope Morrison

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Homology Medicines, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Q32 Bio Securities Corp. • Q32 Bio Australia Pty Ltd • Q32 Bio Operations Inc. ...

QTTB stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$18.17

Low target

$9.00

High target

$22.00

Leerink Partners

Latest filings (excl ownership)

View all

Prospectus supplement

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Regulation FD Disclosure

Prospectus supplement

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Prospectus supplement

Quarterly report

7 Nov 24

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Prospectus supplement

Quarterly report

8 Aug 24

Latest ownership filings

View all

KATHLEEN LAPORTE

ARTHUR TZIANABOS

Jodie Pope Morrison

DAVID S. GRAYZEL

Financial summary

Financial statements Chart QTTB financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	89.73 mm	89.73 mm	89.73 mm	89.73 mm	89.73 mm	89.73 mm
Cash burn (monthly)	2.86 mm	(no burn)	6.27 mm	1.67 mm	6.51 mm	5.58 mm
Cash used (since last report)	14.54 mm	n/a	31.87 mm	8.50 mm	33.07 mm	28.37 mm
Cash remaining	75.19 mm	n/a	57.86 mm	81.22 mm	56.66 mm	61.35 mm
Runway (months of cash)	26.3	n/a	9.2	48.5	8.7	11.0

Beta Read what these cash burn values mean

Financial data from Q32 Bio earnings reports.

Institutional ownership, Q4 2024

QTTB institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	94	75	+25.3%
Opened positions	40	28	+42.9%
Closed positions	21	9	+133.3%
Increased positions	22	17	+29.4%
Reduced positions	11	8	+37.5%

13F shares	Current	Prev Q	Change
Total value	37.78 bn	405.28 bn	-90.7%
Total shares	12.86 mm	11.54 mm	+11.5%
Total puts	40.91 k	0.00	NEW
Total calls	10.12 k	0.00	NEW
Total put/call ratio	4.0	–	–

Largest owners	Shares	Value	Change
Orbimed Advisors	2.25 mm	$7.75 bn	0.0%
Atlas Venture Life Science Advisors	2.09 mm	$7.20 bn	0.0%
CG The Carlyle Group Inc.	1.10 mm	$3.78 bn	0.0%
Atlas Venture Fund X	864.26 k	$808.00 k	0.0%
Acorn Bioventures	803.43 k	$751.00 k	0.0%
Acorn Capital Advisors	803.43 k	$2.76 bn	NEW
Sio Capital Management	697.41 k	$2.40 bn	NEW
Monaco Asset Management SAM	574.82 k	$1.98 bn	NEW
BlackRock	467.44 k	$1.61 bn	+14.4%
Arch Venture	320.48 k	$1.10 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Acorn Capital Advisors	803.43 k	+803.43 k	NEW
Sio Capital Management	697.41 k	+697.41 k	NEW
Monaco Asset Management SAM	574.82 k	+574.82 k	NEW
BMY Bristol-Myers Squibb	200.24 k	-558.90 k	-73.6%
Adage Capital Partners GP, L.L.C.	0.00	-404.41 k	EXIT
FMR	49.18 k	-377.12 k	-88.5%
PFE Pfizer	277.78 k	+277.78 k	NEW
SNY Sanofi	244.08 k	+244.08 k	NEW
Eventide Asset Managment	0.00	-190.00 k	EXIT
Harvard Management	0.00	-162.97 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

QTTB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
24 Feb 25	Shelia M. Violette	Common Stock	Grant	Acquire A	No	No	0	37,500	0.00	61,374
24 Feb 25	Shelia M. Violette	Stock Option Common Stock	Grant	Acquire A	No	No	2.54	56,413	143.29 k	56,413
24 Feb 25	Shelia M. Violette	Stock Option Common Stock	Sale back to company	Dispose D	No	No	16.82	56,413	948.87 k	0
24 Feb 25	Shelia M. Violette	Stock Option Common Stock	Grant	Acquire A	No	No	2.54	17,506	44.47 k	17,506
24 Feb 25	Shelia M. Violette	Stock Option Common Stock	Sale back to company	Dispose D	No	No	7.5	17,506	131.29 k	0
24 Feb 25	Shelia M. Violette	Stock Option Common Stock	Grant	Acquire A	No	No	2.54	13,305	33.79 k	13,305
24 Feb 25	Shelia M. Violette	Stock Option Common Stock	Sale back to company	Dispose D	No	No	7.29	13,305	96.99 k	0
24 Feb 25	Shelia M. Violette	Stock Option Common Stock	Grant	Acquire A	No	No	2.54	32,891	83.54 k	32,891
24 Feb 25	Shelia M. Violette	Stock Option Common Stock	Sale back to company	Dispose D	No	No	7.29	32,891	239.78 k	0
24 Feb 25	Thistle Mary	Stock Option Common Stock	Grant	Acquire A	No	No	2.54	12,767	32.43 k	12,767

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Q32 Bio Announces Results From SIGNAL-AA Part A Clinical Trial Of Bempikibart In Alopecia Areata At 2025 American Academy Of Dermatology Annual Meeting

-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) --

BMO Capital Downgrades Q32 Bio to Market Perform, Lowers Price Target to $3

BMO Capital analyst Etzer Darout downgrades Q32 Bio (NASDAQ:QTTB) from Outperform to Market Perform and lowers the price target from $22 to $3.

This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Piper Sandler Downgrades Q32 Bio to Neutral, Lowers Price Target to $4

BMO Capital Maintains Outperform on Q32 Bio, Lowers Price Target to $22

Press releases

From Benzinga Pro

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) -- WALTHAM,

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

-- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; SIGNAL-AA Part B

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

WALTHAM, Mass., Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.